High levels of erythropoietin are associated with protection against neurological sequelae in African children with cerebral malaria

Proceedings of the National Academy of Sciences of the United States of America

Volumn 105, Issue 7, 2008, Pages 2634-2639

  Casals Pascual, Climent ^a,b   Idro, Richard ^c,d   Gicheru, Nimmo ^c   Gwer, Samson ^c   Kitsao, Barnes ^c   Gitau, Evelyn ^c   Mwakesi, Robert ^c   Roberts, David J ^a   Newton, Charles R J C ^c,e  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b MEDICAL RESEARCH COUNCIL LABORATORIES   (Gambia)

^c KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^d MULAGO HOSPITAL   (Uganda)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Anemia; Plasmodium falciparum; Severe malaria; Vascular endothelial growth factor

Indexed keywords

CYTOKINE; ERYTHROPOIETIN; TUMOR NECROSIS FACTOR; VASCULOTROPIN;

AFRICA; ARTICLE; BLOOD LEVEL; BRAIN MALARIA; CEREBROSPINAL FLUID LEVEL; COMA; CONFIDENCE INTERVAL; CONVULSION; FEMALE; HOSPITAL ADMISSION; HUMAN; KENYA; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; NEUROLOGIC DISEASE; NEUROPROTECTION; PRESCHOOL CHILD; PRIORITY JOURNAL; RISK; STATISTICAL SIGNIFICANCE; MALARIA; METABOLISM; MORTALITY;

PLASMODIUM FALCIPARUM;

AFRICA; CHILD, PRESCHOOL; ERYTHROPOIETIN; FEMALE; HUMANS; MALARIA, CEREBRAL; MALE; NERVOUS SYSTEM DISEASES;

EID: 40649100555     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0709715105     Document Type: Article

References (53)

1. Newton CR, Krishna S (1998) Severe falciparum malaria in children: Current understanding of pathophysiology and supportive treatment. Pharmacol Ther 79:1-53.
2. Carter JA, et al. (2005) Persistent neurocognitive impairments associated with severe falciparum malaria in Kenyan children. J Neurol Neurosurg Psychiatry 76:476-481.
3. Carter JA, et al. (2005) Developmental impairments following severe falciparum malaria in children. Trop Med Int Health 10:3-10.
4. Carter JA, et al. (2004) Increased prevalence of epilepsy associated with severe falciparum malaria in children. Epilepsia 45:978-981.
5. Ngoungou EB, et al. (2006) Epilepsy as a consequence of cerebral malaria in area in which malaria is endemic in Mali, West Africa. Epilepsia 47:873-879.
6. Snow RW, et al. (1997) Relation between severe malaria morbidity in children and level of Plasmodium falciparum transmission in Africa. Lancet 349:1650-1654.
7. Idro R, Jenkins NE, Newton CR (2005) Pathogenesis, clinical features, and neurological outcome of cerebral malaria. Lancet Neurol 4:827-8240.
8. Brewster DR, Kwiatkowski D, White NJ (1990) Neurological sequelae of cerebral malaria in children. Lancet 336:1039-1043.
9. Molyneux ME, Taylor TE, Wirima JJ, Borgstein A. (1989) Clinical features and prognostic indicators in pediatric cerebral malaria: A study of 131 comatose Malawian children. Q J Med 71:441-459.
10. Idro R, Carter JA, Fegan G, Neville BG, Newton CR (2006) Risk factors for persisting neurological and cognitive impairments following cerebral malaria. Arch Dis Child 91:142-148.
11. Carnot P, Deflandre C (1906) Sur l'activité hémopoié tique des différents organes au cours de la régéné ration du sang. C R Acad Sci 143:384-386.
12. Masuda S, et al. (1994) A novel site of erythropoietin production: Oxygen-dependent production in cultured rat astrocytes. J Biol Chem 269:19488-19493.
13. Sakanaka M, et al. (1998) In vivo evidence that erythropoietin protects neurons from ischemic damage. Proc Natl Acad Sci USA 95:4635-4640.
14. Brines ML, et al. (2000) Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci USA 97:10526-10531.
15. Grasso G, et al. (2002) Beneficial effects of systemic administration of recombinant human erythropoietin in rabbits subjected to subarachnoid hemorrhage. Proc Natl Acad Sci USA 99:5627-5631.
16. Liu R, Suzuki A, Guo Z, Mizuno Y, Urabe T. (2006) Intrinsic and extrinsic erythropoietin enhances neuroprotection against ischemia and reperfusion injury in vitro. J Neurochem 96:1101-1110.
17. Siren AL, et al. (2001) Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc Natl Acad Sci USA 98:4044-4049.
18. Wen TC, et al. (2002) Erythropoietin protects neurons against chemical hypoxia and cerebral ischemic injury by up-regulating Bcl-xL expression. J Neurosci Res 67:795-803.
19. Ehrenreich H, et al. (2002) Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med 8:495-505.
20. Casals-Pascual C, et al. (2006) Suppression of erythropoiesis in malarial anemia is associated with hemozoin in vitro and in vivo. Blood 108:2569-2577.
21. Kurtzhals JA, et al. (1997) Reversible suppression of bone marrow response to erythropoietin in Plasmodium falciparum malaria. Br J Haematol 97:169-174.
22. Newton CR, et al. (1997) Severe anemia in children living in a malaria ndemic area of Kenya. Trop Med Int Health 2:165-178.
23. Kaiser K, et al. (2006) Recombinant human erythropoietin prevents the death of mice during cerebral malaria. J Infect Dis 193:987-995.
24. Wenger RH (2002) Cellular adaptation to hypoxia: O2-sensing protein hydroxylases, hypoxia-inducible transcription factors, and O2-regulated gene expression. FASEB J 16:1151-1162.
25. Greenberg DA, Jin K (2005) From angiogenesis to neuropathology. Nature 438:954-959.
26. Wang Y, et al. (2006) Vascular endothelial growth factor improves recovery of sensorimotor and cognitive deficits after focal cerebral ischemia in the rat. Brain Res 1115:186-193.
27. Croll SD, Goodman JH, Scharfman HE (2004) Vascular endothelial growth factor (VEGF) in seizures: A double-edged sword. Adv Exp Med Biol 548:57-68.
28. Zhang ZG, et al. (2000) VEGF enhances angiogenesis and promotes blood-brain barrier leakage in the ischemic brain. J Clin Invest 106:829-838.
29. Chi OZ, Hunter C, Liu X, Weiss HR (2005) Effects of VEGF and nitric oxide synthase inhibition on blood-brain barrier disruption in the ischemic and nonischemic cerebral cortex. Neurol Res 27:864-868.
30. Intiso D, et al. (2004) Tumor necrosis factor alpha serum levels and inflammatory response in acute ischemic stroke patients. Neurol Sci 24:390-396.
31. Barone FC, et al. (1997) Tumor necrosis factor-alpha:Amediator of focal ischemic brain injury. Stroke 28:1233-1244.
32. Grau GE, et al. (1989) Tumor necrosis factor and disease severity in children with falciparum malaria. N Engl J Med 320:1586-1591.
33. Kwiatkowski D, et al. (1990) TNF concentration in fatal cerebral, nonfatal cerebral, and uncomplicated Plasmodium falciparum malaria. Lancet 336:1201-1204.
34. Marti HH (2004) Erythropoietin and the hypoxic brain. J Exp Biol 207:3233-3242.
35. Brines M, Cerami A. (2005) Emerging biological roles for erythropoietin in the nervous system. Nat Rev Neurosci 6:484-494.
36. Villa P, et al. (2003) Erythropoietin selectively attenuates cytokine production and inflammation in cerebral ischemia by targeting neuronal apoptosis. J Exp Med 198:971-975.
37. Wiese L, Kurtzhals JA, Penkowa M. (2006) Neuronal apoptosis, metallothionein expression and proinflammatory responses during cerebral malaria in mice. Exp Neurol 200:216-226.
38. Namiuchi S, et al. (2005) High serum erythropoietin level is associated with smaller infarct size in patients with acute myocardial infarction who undergo successful primary percutaneous coronary intervention. J Am Coll Cardiol 45:1406-1412.
39. O'Donnell A, et al. (2007) Age-related changes in adaptation to severe anemia in childhood in developing countries. Proc Natl Acad Sci USA 104:9440-9444.
40. Fandrey J, et al. (1997) Cobalt chloride and desferrioxamine antagonize the inhibition of erythropoietin production by reactive oxygen species. Kidney Int 51:492-496.
41. Siddiq A, et al. (2005) Hypoxia-inducible factor prolyl 4-hydroxylase inhibition: A target for neuroprotection in the central nervous system. J Biol Chem 280:41732-41743.
42. Smith HJ, Meremikwu M (2003) Iron chelating agents for treating malaria. Cochrane Database Syst Rev, 10.1002/14651858.CD001474.
43. Gordeuk V, et al. (1992) Effect of iron chelation therapy on recovery from deep coma in children with cerebral malaria. N Engl J Med 327:1473-1477.
44. Deininger MH, Winkler S, Kremsner PG, Meyermann R, Schluesener H J (2003) Angiogenic proteins in brains of patients who died with cerebral malaria. J Neuroimmunol 142:101-111.
45. Levy AP, Levy NS, Goldberg MA (1996) Post-transcriptional regulation of vascular endothelial growth factor by hypoxia. J Biol Chem 271:2746-2753.
46. Newton CR, et al. (1991) Intracranial pressure in African children with cerebral malaria. Lancet 337:573-576.
47. Ryuto M, et al. (1996) Induction of vascular endothelial growth factor by tumor necrosis factor alpha in human glioma cells: Possible roles of SP-1. J Biol Chem 271:28220-28228.
48. Nagai A, et al. (2001) Erythropoietin and erythropoietin receptors in human CNS neurons, astrocytes, microglia, and oligodendrocytes grown in culture. J Neuropathol Exp Neurol 60:386-392.
49. Leist M, et al. (2004) Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 305:239-242.
50. Berkley JA, et al. (2001) Diagnosis of acute bacterial meningitis in children at a district hospital in sub-Saharan Africa. Lancet 357:1753-1757.
51. Njuguna P, Newton C (2004) Management of severe falciparum malaria. J Postgrad Med 50:45-50.
52. WHO Expert Committee on Malaria (2000) Twentieth Report (WHO, Geneva).
53. Idro R, Aloyo J (2004) Manifestations, quality of emergency care, and outcome of severe malaria in mulago hospital. Uganda Afr Health Sci 4:50-57.